MYCN and neuroblastoma: Besides the commonly associated MYCN amplification (~20-25%) (2) and 11q loss (~35-45%) (9, 10), other well-known oncogenic drivers of NB include chromosomal abnormalities such as 1p loss and 17q gain that have been individually associated with poor outcomes (11).